Clinical Trials Related to Cyclophosphamide

Related studies linked through entity extraction aliases.

Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

Status: NO_LONGER_AVAILABLE
Phase: N/A

Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)

Status: COMPLETED
Phase: PHASE3

Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma

Status: TERMINATED
Phase: PHASE2

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Status: RECRUITING
Phase: PHASE1

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

Status: TERMINATED
Phase: PHASE1/PHASE2

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Status: COMPLETED
Phase: PHASE3

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

Non-Viral TCR Gene Therapy

Status: WITHDRAWN
Phase: PHASE2

Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

Status: COMPLETED
Phase: PHASE1

Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

Status: COMPLETED
Phase: PHASE1

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

Status: COMPLETED
Phase: PHASE1

Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Status: RECRUITING
Phase: PHASE2

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Status: RECRUITING
Phase: PHASE1/PHASE2

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

Status: TERMINATED
Phase: PHASE2

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Status: COMPLETED
Phase: PHASE1

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Status: COMPLETED
Phase: PHASE1/PHASE2

A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

Status: UNKNOWN
Phase: PHASE2

Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

Status: COMPLETED
Phase: PHASE1

Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2